Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.26 USD | +1.07% | -0.16% | -6.92% |
03-08 | Truist Securities Adjusts Price Target on OrthoPediatrics to $32 From $31, Maintains Hold Rating | MT |
03-07 | Transcript : OrthoPediatrics Corp., Q4 2023 Earnings Call, Mar 07, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.92% | 720M | D+ | ||
+12.07% | 128B | A- | ||
-9.04% | 10.65B | A- | ||
+0.91% | 8.82B | C | ||
+16.72% | 7.19B | C | ||
+25.15% | 4.99B | B+ | ||
+7.17% | 3.4B | C- | ||
-1.36% | 3.03B | B- | ||
-8.73% | 2.14B | - | - | |
-10.15% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KIDS Stock
- Ratings OrthoPediatrics Corp.